Topiramate Added to Metformin for Obesity Control in Women With Polycystic Ovary Syndrome
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgae637 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Lucas Bandeira Marchesan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Gynecological Endocrinology Unit, Division of Endocrinology, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS 90035-003, Brazil. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Topiramate, Metformin, Obesity. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul.
Abstract (Originalsprache)
Context
Polycystic ovary syndrome (PCOS) is often linked with obesity, and weight management can improve endocrine and cardiometabolic features.
Objective
This work aimed to evaluate the effects of adding topiramate (TPM) to metformin (MTF) on weight control and hormonal and metabolic outcomes in women with PCOS.
Methods
In a randomized, double-blind, placebo-controlled trial, participants with PCOS and body mass index of 30 or greater, or 27 or greater associated with hypertension, type 2 diabetes, or dyslipidemia followed a 20 kcal/kg diet in addition to 850 mg of MTF or a previous MTF regimen. They were randomly assigned to receive either TPM or placebo (P) alongside MTF. Anthropometric measurements, blood pressure, modified Ferriman-Gallwey score (mFGS), and adverse events were assessed every 4 weeks for 6 months. The primary end point was the percentage change in body weight from baseline in both groups. Secondary end points included changes in clinical, cardiometabolic, and hormonal parameters and psychosocial features.
Results
Thirty-one participants were in the MTF + P group and 30 in the MTF + TPM group. The MTF + TPM group showed greater mean weight loss at 3 months (−3.4% vs −1.6%; P = .03) and 6 months (−4.5% vs −1.4%; P = .03). Both groups had improved androgens, lipids, and psychosocial scores. Participants with 3% or greater weight loss at 6 months had improved mFGS (8.4 to 6.5; P = .026). Paresthesia was more common in the MTF + TPM group (23.3% vs 3.2%; P = .026).
Conclusion
Combining TPM with MTF and a low-calorie diet may be an effective, low-cost, easy-to-use, and safe strategy for weight management in women with PCOS, with mild adverse effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gynecological Endocrinology Unit, Division of Endocrinology, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS 90035-003, Brazil.
- Division of Endocrinology, Hospital Nossa Senhora da Conceição (HNSC), Porto Alegre, RS 91350-200, Brazil.
- Postgraduate Program in Endocrinology, Medical School, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS 90035-003, Brazil.
- Department of Physiology, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS 90035-003, Brazil.
ORCID-Profile: Lucas Bandeira Marchesan, Thais Rasia da Silva, Poli Mara Spritzer
Förderung
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul
Zitieren
APA
Marchesan, L. B., da Silva, T. R., & Spritzer, P. M. (2025). Topiramate Added to Metformin for Obesity Control in Women With Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae637
Vancouver
Marchesan LB, da Silva TR, Spritzer PM. Topiramate Added to Metformin for Obesity Control in Women With Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae637
BibTeX
@article{Marchesan2025,
author = {Marchesan, Lucas Bandeira and da Silva, Thais Rasia and Spritzer, Poli Mara},
title = {Topiramate Added to Metformin for Obesity Control in Women With Polycystic Ovary Syndrome},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgae637}
}
EUVIMED